Najafi Mohammad Reza, Najafi Mohammad Amin, Nasr Zahra
Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran ; Isfahan Neurosciences Research Centre (INRC), Isfahan University of Medical Sciences, Isfahan, Iran.
Medical student, Isfahan University of Medical Sciences, Faculty of Medicine, Isfahan, Iran ; Isfahan Neurosciences Research Centre (INRC), Isfahan University of Medical Sciences, Isfahan, Iran.
Iran J Child Neurol. 2016 Summer;10(3):13-23.
Growing evidence indicates the safety and well toleration of treatment by Disease-modifying in children suffering multiple sclerosis (MS). The treatment is not straight forward in a great number of patients, thus patients with pediatric MS must be managed by experienced specialized centers. Common treatments of multiple sclerosis for adults are first-line therapies. These therapies (firstline) are safe for children. Failure in treatment that leads to therapy alteration is almost prevalent in pediatric MS. Toleration against current second-line therapies has been shown in multiple sclerosis children. Oral agents have not been assessed in children MS patients. Although clinical trials in children are insufficient, immunomodulating managed children, experience a side effect similar to the adult MS patients. However, further prospective clinical studies, with large sample size and long follow-up are needed to distinguish the benefits and probable side effects of pediatric MS therapies.
越来越多的证据表明，疾病修饰治疗对患有多发性硬化症（MS）的儿童具有安全性且耐受性良好。在许多患者中，这种治疗并非一帆风顺，因此患有小儿MS的患者必须由经验丰富的专业中心进行管理。成人多发性硬化症的常见治疗方法是一线疗法。这些疗法（一线疗法）对儿童是安全的。治疗失败导致治疗方案改变在小儿MS中几乎很普遍。多发性硬化症儿童已显示出对当前二线疗法的耐受性。口服药物尚未在儿童MS患者中进行评估。尽管针对儿童的临床试验不足，但接受免疫调节治疗的儿童所经历的副作用与成年MS患者相似。然而，需要进一步进行大样本量和长期随访的前瞻性临床研究，以区分小儿MS疗法的益处和可能的副作用。
